The pathophysiology of preeclampsia (PE) is thought to be endothelial dysfunction responsible for the maternal signs of de novo hypertension and proteinuria after 20 weeks. Current concepts suggest that the pathophysiology of preeclampsia and intrauterine growth retardation results from an imbalance of angiogenic factors. A new angiogenic factor EG-VEGF (Endocrine Gland- Derived Vascular Endothelial Growth Factor) also known as Prokineticin 1 (PROK1) appears to be emerging in the pathophysiology of PE. EG-VEGF is a circulating factor which belongs to the family of prokinetics. Dr Alfaidy's MAB2 team at the Cancer and Infections Biology Laboratory (U1292 Biosanté INSERM / UGA / CEA, CEA Grenoble) demonstrated its key role in the control of key processes in placental development and provided evidence through the development of an animal model of preeclampsia. EG -VEGF is directly involved in the development of Pre-Eclampsia. Few studies have evaluated the expression of EG-VEGF in the human placenta.
Study Type
OBSERVATIONAL
Enrollment
35
a placenta pathological examination will be analyzed to examine quantification of EG-VEGF, PROKR1 and PROKR2 receptors.
Chu Saint-Etienne
Saint-Etienne, France
Immuno-localization of EG-VEGF staining (ImageJ®) by immunohistochemistry
Measured by placenta pathological examination (immunohistochemistry technical).
Time frame: At delivery
Quantification of EG-VEGF staining (ImageJ®) by immunohistochemistry
Measured by placenta pathological examination (immunohistochemistry technical).
Time frame: At delivery
Immuno-localization of the staining of PROKR1 (ImageJ®) by immunohistochemistry
Measured by placenta pathological examination (immunohistochemistry technical).
Time frame: At delivery
Quantification of the staining of PROKR1 (ImageJ®) by immunohistochemistry
Measured by placenta pathological examination (immunohistochemistry technical).
Time frame: At delivery
Immuno-localization of the staining of PROKR2 (ImageJ®) by immunohistochemistry
Measured by placenta pathological examination (immunohistochemistry technical).
Time frame: At delivery
Quantification of the staining of PROKR2 (ImageJ®) by immunohistochemistry Measure by placenta pathological examination (immunohistochemistry technical).
Measured by placenta pathological examination (immunohistochemistry technical).
Time frame: At delivery
Presence of at least one chronic maternal pathologies describe below
diabetes, hypertension, kidney disease, Systemic Lupus Erythematosus (SLE), antiphospholipid syndrome
Time frame: At delivery
Obstetric history
Pre-Eclampsia (PE) and intra uterine growth retardation (IUGR), term of onset and severity of Pre-Eclampsia (PE)
Time frame: At delivery
Presence of an anticoagulant treatment
treatment by aspirin or Heparin or low molecular weight heparins (LMWH)
Time frame: At delivery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.